Echo Therapeutics Announces Issuance of New Patent for Symphony(TM) Transdermal Continuous Glucose Monitoring System
FRANKLIN, Mass., Oct 16, 2008 /PRNewswire-FirstCall via COMTEX/ -- Echo Therapeutics announced the issuance of U.S. Patent 7,432,069 covering compositions and methods for the preparation of a polyethylene glycol (PEG)-based hydrogel as a key component of Echo's Symphony(TM) Transdermal Continuous Glucose Monitoring (tCGM) System. "Our proprietary PEG hydrogel, specifically designed to enable transdermal biosensing, is characterized by excellent stability, sensitivity, integrity and biocompatibility, making our Symphony tCGM System a desirable system for non-invasive continuous glucose monitoring," stated Patrick Mooney, M.D., Echo's Chairman and CEO. "This patent is critical to our intellectual property strategy for protecting our leading position in non-invasive, tCGM markets worldwide."
http://www.marketwatch.com/news/story/echo-therapeutics-announces-issuance-new/story.aspx?guid=%7B423582AE-A88E-4624-B5A4-3BDBF941493D%7D&dist=TQP_Mod_pressN
http://www.reuters.com/article/pressRelease/idUS79215+02-Jan-2008+PRN20080102
No comments :
Post a Comment